BIRIPERONE

Details

Stereochemistry	RACEMIC
Molecular Formula	C24H26FN3O
Molecular Weight	391.4811
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC1=CC=C(C=C1)C(=O)CCCN2CCN3CC4=C(CC3C2)C5=CC=CC=C5N4

InChI

InChIKey=YCNCIZWAGQTWBI-UHFFFAOYSA-N

InChI=1S/C24H26FN3O/c25-18-9-7-17(8-10-18)24(29)6-3-11-27-12-13-28-16-23-21(14-19(28)15-27)20-4-1-2-5-22(20)26-23/h1-2,4-5,7-10,19,26H,3,6,11-16H2

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21206602 | https://www.passeidireto.com/arquivo/22911694/2016-equine-prohibited-substances-list/2

Biriperone (also known as Centbutindole) was developed as an antipsychotic drug. It has shown effective antipsychotic activity in schizophrenic patients. Biriperone acts as a dopamine antagonist, and also as a blocker of 5HT(2) receptor. Clinically the drug has passed through phase I, II & III clinical trials successfully, however, the use of this drug was banned.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL339 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17869521	Antagonist 2778		7.88 null [pKi]
Serotonin 2a (5-HT2a) receptor 231 Target ID: CHEMBL322 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17869521	Antagonist 2778		7.619 null [pKi]

PubMed

Title	Date	PubMed
Effect of dopamine agonists and antagonists on the lorazepam withdrawal syndrome in rats.	2000 Mar	10744342
Metabolism and excretion of centbutindole (neuroleptic) in rats after oral administration.	2002 Dec	12542891
Comparative efficacy of centbutindole & risperidone in schizophrenia.	2002 Oct	21206602
Pharmacokinetics, in-situ absorption and protein binding studies of a new neuroleptic agent centbutindole in rats.	2003 Jun	12791412

Sample Use Guides

In Vivo Use Guide

Patietns were randomly allocated to receive either 4.5mg of centbutindole or 6 mg of risperidone. The drug was formulated in capsules identical in colour, shape and size. Each capsule contained centbutidole (1.5 mg) or risperidone (2 mg). Initial dose was 1 Capsule twice a day for three days increasing to 1 capsule in the morning and 2 capsule at bed time through out the study period of 8 weeks.

Route of Administration: Oral

Name

Type

Language

BIRIPERONE

Official Name

English

biriperone [INN]

Common Name

English

(±)-4'-FLUORO-4-(3,4,6,7,12,12A-HEXAHYDROPYRAZINO(1',2':1,6)PYRIDO(3,4-B)INDOL-2(1H)-YL)BUTYROPHENONE

Common Name

English

NSC-143691

Code

English

BIRIPERONE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C28197